Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Yoga Effect on Quality of Life Study Among Patients with Idiopathic Pulmonary Fibrosis (YES-IPF).

Created on 15 Oct 2026

Authors

Suha Kadura, Soumik Purkayastha, Josh Benditt, Amit Anand, Bridget Collins, Miguele De Quadros, Mafara Hobson, M J Biswas, Lawrence Ho, Cathie Spino, Ganesh Raghu

Published in

Respiratory medicine. Pages 109194. Oct 14, 2026. Epub Oct 14, 2026.

Abstract

Patients with idiopathic pulmonary fibrosis (IPF) have poor health-related quality of life.
To explore the feasibility and potential impact of a modified yoga program on health-related quality of life in patients with IPF compared with usual care.
We conducted a randomized, controlled, nonblinded, 12-week pilot clinical trial with two arms involving 63 adults with IPF diagnosed according to the 2018 ATS/ERS/JRS/ALAT clinical practice guideline. The yoga arm attended one-hour virtual group sessions twice weekly for 12 weeks, consisting of seated postures, breathing exercises, and meditation designed for patients with IPF, while the control arm continued usual care.
ments: Health-related quality of life was assessed using seven patient-reported outcome measures and their associated domains.
Sixty of 63 randomized participants completed the week-12 assessment and comprised the analysis cohort; their mean age was 73.4 years (SD, 8.2). Statistically significant improvements favoring yoga were seen in the Living with Idiopathic Pulmonary Fibrosis (L-IPF) cough domain (-9.29 points, 95% CI -18.37 to -0.20; p=0.045; SMD=-0.36), the L-IPF total score (-7.11, 95% CI -13.15 to -1.06; p=0.022; SMD=-0.38), and the R-scale-PF cough domain (-1.18, 95% CI -2.27 to -0.10; p=0.034; SMD=-0.45).
In this exploratory pilot trial, a modified yoga program was feasible and well tolerated and was associated with improvements in selected patient-reported outcome domains. These findings are hypothesis-generating and warrant evaluation in a larger, adequately powered trial.

PMID:
42874938
Bibliographic data and abstract were imported from PubMed on 15 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 13
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement